Population-Based Estimates of Survival and Cost for Metastatic Melanoma
Authors:
Open Access
- 1 October 2015
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 22 (5) , 326-332
Abstract
Background Fewer than half of all patients with metastatic melanoma survive more than 1 year. Standard treatments have had little success, but recent therapeutic advances offer the potential for an improved prognosis. In the present study, we used population-based administrative data to establish real-world baseline estimates of survival outcomes and costs against which new treatments can be compared. Methods Data from administrative databases and patient registries were used to find a cohort of patients with metastatic melanoma in Ontario. To identify individuals most likely to receive new treatments, we focused on patients eligible for second-line treatment. The identified cohort had two characteristics:no surgical resection beyond primary skin excision, and receipt of first-line systemic therapy. Results Patient characteristics, Kaplan–Meier survival curves, and mean costs are reported. Of the 33,585 patients diagnosed with melanoma in Ontario from 1 January 1991 to 31 December 2010, 278 met the study inclusion criteria. Average age was 63 years, and 62% of the patients were men. Overall survival was estimated to be 19%, 12%, and 6% at 12, 24, and 60 months respectively. Mean survival time was 11.5 months, and mean cost was $30,685. Conclusions Our baseline estimates indicate that survival outcomes are poor and costs are high for patients receiving standard treatment. Understanding the relative improvement accruing from any new treatment requires a comparison with the existing standard of care.Keywords
This publication has 21 references indexed in Scilit:
- Utilization and costs of home care for patients with colorectal cancer: a population-based studyCMAJ Open, 2014
- Randomised controlled trials and population-based observational research: partners in the evolution of medical evidenceBritish Journal of Cancer, 2014
- Vemurafenib and ipilimumab: New agents for metastatic melanomaAmerican Journal of Health-System Pharmacy, 2013
- Melanoma Treatment CostsAmerican Journal of Preventive Medicine, 2012
- Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990–2009PLOS ONE, 2012
- Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)European Journal of Cancer, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- End-of-Life Care for Lung Cancer Patients in the United States and OntarioJNCI: Journal of the National Cancer Institute, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Treatment of metastatic melanoma: an overview.2009